Clinical Trial: Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06912087) titled 'Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC' on Jan. 31.

Brief Summary: This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerated dose (MTD) and recommended Phase II dose (RP2D) while also exploring efficacy outcomes, including progression-free survival (PFS) and overall survival (OS).

Study Start Date: June 05

Study Type: INTERVENTIONAL

Condition: ...